According to a new report Europe Antibiotics Market, published by KBV research, the Europe Antibiotics Market would witness market growth of 4.9% CAGR during the forecast period (2020-2026).
The Germany market dominated the Europe Antibiotics Market by Country in 2019, growing at a CAGR of 4.2 % during the forecast period. The UK market is exhibiting a CAGR of 3.9% during (2020 - 2026). Additionally, The France market is poised to grow at a CAGR of 6.2% during (2020 - 2026).
The Cephalosporin market dominated the Russia Antibiotics Market by Drug Class in 2019, growing at a CAGR of 3.9 % during the forecast period. The Penicillin market is estimated to grow at a CAGR of 3.8% during (2020 - 2026). The Fluoroquinolone market is witnessing a CAGR of 6.6% during (2020 - 2026). Additionally, The Macrolides market is expected to witness highest CAGR of 6.7% during (2020 - 2026).
The Cell Wall Synthesis Inhibitors market dominated the Italy Antibiotics Market by Action Mechanism in 2019, thereby, achieving a market value of $314.3 million by 2026. The Protein Synthesis Inhibitors market is experiencing a CAGR of 4.2% during (2020 - 2026). Additionally, The Mycolic Acid Inhibitors market would showcase highest CAGR of 6.9% during (2020 - 2026).
Full Report: https://www.kbvresearch.com/europe-antibiotics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.
By Action Mechanism
By Drug Class
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
